0001209191-23-048199.txt : 20230905 0001209191-23-048199.hdr.sgml : 20230905 20230905170845 ACCESSION NUMBER: 0001209191-23-048199 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230901 FILED AS OF DATE: 20230905 DATE AS OF CHANGE: 20230905 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Balthaser Kevin CENTRAL INDEX KEY: 0001957554 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37581 FILM NUMBER: 231236810 MAIL ADDRESS: STREET 1: C/O ACLARIS THERAPEUTICS, INC. STREET 2: 640 LEE ROAD, SUITE 200 CITY: WAYNE STATE: PA ZIP: 19087 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aclaris Therapeutics, Inc. CENTRAL INDEX KEY: 0001557746 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 460571712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 640 LEE ROAD STREET 2: SUITE 200 CITY: WAYNE STATE: PA ZIP: 19087 BUSINESS PHONE: 484-324-7933 MAIL ADDRESS: STREET 1: 640 LEE ROAD STREET 2: SUITE 200 CITY: WAYNE STATE: PA ZIP: 19087 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-09-01 0 0001557746 Aclaris Therapeutics, Inc. ACRS 0001957554 Balthaser Kevin C/O ACLARIS THERAPEUTICS, INC. 640 LEE ROAD, SUITE 200 WAYNE PA 19087 0 1 0 0 Chief Financial Officer 0 Common Stock 2023-09-01 4 M 0 1000 A 6256 D Common Stock 2023-09-01 4 F 0 285 7.90 D 5971 D Restricted Stock Units 2023-09-01 4 M 0 1000 0.00 D Common Stock 1000 1000 D Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. The shares underlying these restricted stock units vest over a period of two years, with one-half of the shares vesting on each of September 1, 2023 and September 1, 2024, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. /s/ Mark Ballantyne, Attorney-in-Fact 2023-09-05